What You Should Know:

• In a significant leap forward for inpatient care, Caregility is proud to introduce a new class of adaptive telehealth edge devices designed to seamlessly support hybrid care models that bring remote clinicians and artificial intelligence (AI) capabilities into bedside workflows at the point of care.
• The groundbreaking APS200 Duo is the company’s first dual-camera, all-in-one system with onboard edge computing and a powerful dedicated graphics engine. The APS200 Duo includes a wide-angle camera for remote patient observation and a high-definition 40x power zoom camera for virtual nursing programs and remote patient examinations.

Revolutionizing Inpatient Care: Next-Gen Telehealth Devices for Seamless Virtual Clinical Interactions

The redesigned APS100 Pro, a second-generation all-in-one system with a wide-angle camera for remote patient observation, can be expanded with the APS FlexCam—a high-definition 40x power zoom video camera for virtual nursing programs. Both devices support flexible wiring options, including Power-Over-Ethernet (PoE+).

These advanced telehealth edge devices, tailored for inpatient settings, not only offer superior audio and video capabilities but also address clinical staffing shortages and enhance patient monitoring with AI-driven insights. They integrate with the Caregility Cloud™ virtual care platform, supporting various clinical applications. Multiple audio and video streams facilitate concurrent workflows like continuous remote patient observation and specialty consultations.

The AI-enhanced devices enable seamless virtual clinical interactions, improving efficiency and quality of patient care. Dual-camera configurations allow for virtual encounters and AI-supported continuous patient monitoring simultaneously, aiding in faster intervention. Advanced microphone arrays and high-quality speakers enhance realistic encounters and support AI applications like ambient documentation.

The APS200 Duo, APS100 Pro, and APS FlexCam mark a significant advancement in hospital-based telehealth, supporting patients and acting as a workforce multiplier. Key features include built-in edge computing, versatile connectivity options, dual HD cameras with 1080p resolution, 40x power zoom, 5x wide-angle field of view, night vision, and seamless integration with various systems.

These FDA-registered Class 1 medical devices can integrate with digital TVs and Interactive Patient Console systems, optimizing space. The Caregility devices include a wall-mounted vLert button for initiating on-demand sessions with virtual clinicians. Every device is self-healing, proactively monitored, and remotely managed for reliability.

OhioHealth implemented 66 APS100 Pro devices in its Patient Room of the Future initiative at Pickerington Methodist Hospital, showcasing early market adoption in scaling AI-enabled telehealth cost-effectively to every patient room.

“From ordering meals to watching educational videos and managing medication schedules, the intuitive technology aims to provide a more personalized hospital stay,” said Tom Gutman, OhioHealth Senior Consultant of Learning Simulation. “The addition of a camera above the TV allows patients to speak virtually with nurses, specialists, or family members. The positive impact is evident to both staff and patients alike.”

What You Should Know:

• ShiftMed, the leader in on-demand workforce technology, announces today the launch of ShiftAdvisor, a new AI-powered feature set to transform nurse scheduling and elevate the staffing efficiency of healthcare facilities.
• This solution is designed to benefit both healthcare professionals (HCPs) and facilities by optimizing shift scheduling, ensuring providers find the best shifts with minimal cancellation risks, and simultaneously enabling facilities to achieve optimal staffing levels.

AI-Powered ShiftAdvisor Delivers Tailored Recommendations for Professionals and Facilities

Healthcare professionals who have completed a minimum of four shifts using the application will now receive tailored shift recommendations based on their individual preferences for day, time, pay, and location. ShiftAdvisor introduces an efficient approach to shift selection by utilizing AI algorithms that seamlessly align with the unique skills and financial objectives of healthcare providers (HCPs), thereby optimizing their earning potential. The system offers a personalized shift recommendation feature, serving as both a time-saving tool and a strategic aid for providers to enhance their work schedules.

Through the receipt of AI-powered suggestions tailored to their distinct preferences, HCPs can make well-informed decisions, leading to a more satisfying and financially rewarding experience. This emphasis on personalization grants providers greater control over their schedules within the app, simplifying the process.

Simultaneously, healthcare facilities benefit from an intelligent system that minimizes the likelihood of last-minute cancellations, resulting in improved operational efficiency and cost savings. This dual-benefit approach underscores ShiftMed’s commitment to delivering user-centric solutions, ensuring a streamlined scheduling experience for both healthcare professionals and facilities on the platform. ShiftMed’s dedication to innovation in workforce management is evident in this latest development, highlighting its capability to provide cutting-edge solutions for both healthcare professionals and facilities. This is further emphasized by the company’s notable growth and strategic collaborations, including partnerships with esteemed institutions such as SSM Health, Hennepin Healthcare, and Presbyterian Healthcare Services.

“The customized shift suggestions in ShiftAdvisor is a targeted tool designed to meet the specific needs of our HCPs and enhance their experience on the ShiftMed platform,” explained Todd Walrath, CEO of ShiftMed. “Our commitment to improving the state of the healthcare workforce is evident in this new feature, which not only empowers users but also delivers added benefits to our facility partners. ShiftAdvisor exemplifies our dedication to creating a platform that caters comprehensively to healthcare professionals’ diverse and evolving needs.”

What You Should Know:

• Carallel, the leading provider of holistic support, guidance and assistance for family caregivers, and myFloc, an AARP Innovation Labs portfolio company that connects family, friends and caregivers on a common expense platform, today announced a strategic partnership to tackle some of the most complex challenges that come with being a family caregiver.
• Caregivers help their loved ones in a variety of ways, from health advocacy (56%) to monitoring health conditions (71%) to managing activities of daily living (60%), according to a 2020 AARP report. But, beyond these well-recognized responsibilities, nearly all (92%) caregivers are also financial caregivers. They help manage their loved one’s money and other assets and help with everyday financial matters.

Empowering Holistic Care: Carallel and myFloc Partnership

Managing finances can be intricate and emotionally charged, leading to conflicts among family members. Adding to the complexity is the rising prevalence of elder financial exploitation, as highlighted in a 2022 AARP report that revealed a more than twofold increase since the onset of the COVID-19 pandemic in 2020.

The partnership between Carallel and myFloc combines top-notch solutions to simplify caregiving. Caregivers on the Carallel platform now have seamless access to myFloc, easing financial challenges for family, friends, and non-kin caregivers.

Carallel and myFloc eagerly anticipate extending these enhanced benefits to customers, offering a comprehensive solution through a single contract to empower employees, members, and clients. MyFloc’s financial platform, designed for older adults and caregivers, features a prepaid debit card-based system. This system allows care recipients to maintain financial autonomy, monitor expenditures, and seek assistance on their terms. Moreover, care recipients can invite selected team members to use myFloc cards, complete with specific controls, permissions, and notifications, with the option to provide visibility into the entire myFloc account.

“Managing a loved one’s finances and dealing with day-to-day expenses is incredibly challenging for reasons that go well beyond the math,” said Shara Cohen, CEO of Carallel. “We hear from caregivers every day struggling within their families about this topic, worrying that their loved one is being taken advantage of or trying to protect against scams. myFloc offers a really important solution for this all-too-common challenge.”

What You Should Know:

• DeepScribe, the leading enterprise-grade AI medical scribe, today announced key updates to its integration with Epic Systems’ electronic health record (EHR).
• DeepScribe’s recently launched Customization Studio, which allows users to build custom models to support unique specialty and organizational needs, is now fully integrated with Epic’s SmartData elements. This makes DeepScribe the first solution to harmonize an extensive suite of customization options with Epic’s interface and establishes a new benchmark for ambient solutions on their platform. 

Revolutionizing Clinical Documentation: DeepScribe’s Enhanced Integration with Epic Transforms Charting Efficiency

In collaboration with Epic and Covenant HealthCare, DeepScribe has refined its integration based on feedback from clinicians, technical experts, and organizational stakeholders. This user-centric approach enables DeepScribe to seamlessly incorporate highly personalized documentation into a patient’s chart fields, resulting in a remarkable reduction of up to 75 percent in after-hours documentation for Covenant clinicians. 

Furthermore, this partnership has laid the groundwork for SmartData compatibility on the Epic platform, offering improved back-end communication and unlocking the full potential of DeepScribe’s Customization Studio across various Epic instances. This advancement not only enhances the user experience but also sets the stage for other ambient solutions to adopt similar innovations.

“We worked tirelessly with DeepScribe developers to enhance the integration in a way that meets clinical needs more holistically,” said Frank Fear, CIO of Covenant HealthCare. “The primary objective for us was to help DeepScribe establish compatibility with Epic’s SmartData elements. With that functionality built out, we can now properly leverage all of DeepScribe’s unique features in a really cohesive manner. That seamlessness between platforms is empowering us to streamline workflows and improve the clinician-patient experience.”

What You Should Know:

• Hims & Hers Health, Inc., the leading health and wellness platform, and Connecticut’s most transformative health system, Hartford HealthCare (HHC), today announced a strategic partnership that broadens access to in-person healthcare services. 
• The collaboration provides patients with an enhanced and connected healthcare experience when they need care outside the Hims & Hers platform. Licensed medical providers on the platform will be able to seamlessly refer patients to HHC’s distinguished primary and specialty care provider network, when necessary. This can include when Hims & Hers customers have more complex health histories or medical needs, those that may require additional in-person follow-up care or evaluations or are in need of care for conditions not currently supported by the Hims & Hers platform

Enhancing Specialized Care: A Focus on Cardiovascular Health with HHC

Hims & Hers reinforces its commitment to accessible, high-quality care by integrating the esteemed Connecticut-based healthcare system, HHC, into its growing provider network. With this addition, the company’s medical system partner network now spans 11 states and Washington, D.C.

As Hims & Hers expands into personalized treatments, such as Heart Health by Hims and Weight Loss by Hims & Hers, the inclusion of HHC further strengthens the company’s emphasis on quality care. HHC’s renowned Heart & Vascular Institute, a national leader in cardiovascular disease care, offers personalized treatments and advanced cardiac procedures, making it a significant addition to the expanding network.

“We partnered with Hartford HealthCare because of its unwavering commitment to delivering exceptional care, embracing innovation, and fostering a culture of compassion,” said Hims & Hers Chief Medical Officer Patrick Carroll, MD. “With a focus on patient well-being, cutting-edge treatments, and a dedicated team of healthcare professionals, we know our customers in Connecticut will always receive the best care when they need to see a specialist for treatment beyond our platform.”

What You Should Know:

• Shimmer, an innovative online coaching platform designed for adults with ADHD today announces it has raised $2.2 million in seed funding.
• The round was co-led by Worklife Ventures and SeedtoB Capital, with participation from Koa Labs, Aglaé Ventures, and Gaingels. The company plans to expand its AI-focused product development and launch a scientific study researching ADHD coaching outcomes under the auspices of leading universities in the United States and the United Kingdom.

Revolutionizing Personal Growth with Shimmer: AI-Enhanced ADHD Coaching

Discover a transformative journey through live sessions with Shimmer’s expert ADHD coaches, leveraging the platform’s cutting-edge AI capabilities. Uncover personalized strategies and practical steps tailored to bring about lasting change, fostering improved relationships and career progression. Shimmer serves as a dedicated guide, helping members plan and track their daily aspirations with precision.

Explore the repercussions of untreated adult ADHD, such as relationship strain, increased stress, disruptions in personal and professional life, and potential substance abuse. Delve into the challenges, including difficulties in concentration, completing daily tasks, and achieving long-term goals. Shimmer’s coaching approach is designed to alleviate these issues, providing a pathway to self-advocacy and empowerment.

Shimmer’s Co-founder and CEO, Chris Wang, who has ADHD, emphasizes the company’s mission: “Living with ADHD can be isolating and challenging. At Shimmer, we’re dedicated to providing the support and tools needed for individuals to feel empowered and successful. Our platform is designed to be a powerful tool to help people reach their full potential and lead fulfilling lives.” 

Since its launch in October 2022, Shimmer’s expert ADHD coaches have provided more than 10,000 coaching sessions to a global audience. The company also provides pro bono coaching to government agencies, universities and several nonprofits. Going forward, Shimmer plans to expand its services to companies building inclusive environments for their workforce.

What You Should Know:

• Vita Health, the first provider of clinically validated suicide prevention through innovative care management, announced today the close of a $22.5M Series A funding round.
• The funding will support the rapid expansion of life-saving services targeting youth and adults nationwide. The Vita behavioral health care pathways are based on the founding team’s successful clinical trials published in JAMA, The American Journal of Psychiatry and thousands of patient encounters demonstrating reductions in suicide attempts by more than 60% and deaths by up to 80%.

Diverse Consortium Backs Vita Health’s Specialized Telehealth Solutions for Mental Health Crisis

A diverse group of investors, including LFE Capital, Athyrium Capital Management, Flare Capital Partners, CVS Health Ventures, CU Healthcare Innovation Fund, Connecticut Innovations, and HopeLab, participated in the funding round for Vita Health. Vita Health initially aimed to tackle the rising suicide rates across all age groups but has expanded its mission to address the broader youth mental health crisis, covering conditions such as anxiety and depression.

 Suicide ranks as the second leading cause of death among teens and college students, and is a top-five killer for adults, according to the Center for Disease Control and Prevention. In 2021, there were over 1.7 million suicide attempts in the US. Vita Health stands out as the only telehealth provider specializing in suicide care, while also offering teletherapy and psychiatry services for various behavioral health conditions. Founded by a consortium of leading suicide risk experts and seasoned behavioral health innovators, Vita Health’s approach aims to address the root causes behind suicide.

“Our collective motivation was to shift a very deadly curve in our society that has far reaching and lasting implications for all involved,” says Vita Health co founder and chief executive officer, Lynn Hamilton. “We are humbled by the participation from a broad group of sophisticated, experienced, and strategic investors. With a growing roster of health plan partners, provider partners, employers, colleges and universities, we are expanding our reach to directly address the most challenging mental health problems in the U.S.”

What You Should Know:

• Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced a research collaboration with NVIDIA to accelerate the development and adoption of advanced computer vision solutions in life sciences.
• Deepcell will incorporate NVIDIA AI into its single cell analysis technology, working collaboratively with NVIDIA to codevelop new uses for generative AI and multimodal applications in cell biology. The joint collaboration aims to advance understanding of cell morphology, and ultimately accelerate the use of AI-powered cellular analysis in cell biology and translational research across a broad swath of applications including cancer, stem cell, and cell therapy.

 Revolutionizing Life Sciences Through Cutting-Edge AI Collaboration

Deepcell, in partnership with NVIDIA, is poised to revolutionize life sciences by harnessing the power of multimodal generative AI. This collaboration aims to develop innovative algorithms, utilizing NVIDIA’s Clara suite and computing expertise, to enhance cell image analysis. Deepcell’s REM-I platform, set to be fully commercialized in 2024, integrates high-dimensional cell morphology analysis and sorting capabilities, enabling groundbreaking discoveries in cancer biology, developmental biology, stem cell biology, gene therapy, and more. The synergy between Deepcell’s technological strengths and NVIDIA’s resources promises to usher in a new era of insights and advancements in the field.

“Deepcell has catalyzed the field of morpholomics and showcased the benefits of a

revolutionary new method for single-cell analysis using brightfield cell imaging and artificial

intelligence,” said Mahyar Salek, Ph.D., Cofounder, President, and Chief Technology Officer at

Deepcell. “As we look to the future, we see many possibilities for incorporating multimodal and

generative AI into our platform, and leveraging our proprietary database of billions of cell

images to train additional AI models. Our relationship with NVIDIA will help us accelerate such

enhancements, and bring these advancements to our customers, enabling new discoveries at

unprecedented speed.”

What You Should Know:

• Ultima Genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and Quest Diagnostics, the nation’s leading provider of diagnostic information services, today announced a collaboration involving Ultima’s next generation sequencing (NGS) technology in oncology and other clinical areas. 

Expanding Horizons in Cost-Effective Whole Genome Sequencing

The collaboration aims to enhance patient access, affordability, and outcomes by expanding the use of cost-efficient whole genome sequencing, particularly in areas like solid-tumor minimal residual disease (MRD) testing. Quest plans to utilize Ultima’s technology, such as the UG 100™ System, to develop lab-developed tests, including its Haystack solid-tumor MRD™ technology.

 Ultima’s platform offers the capability to sequence an entire genome for $100 and stands out for its sensitivity in detecting rare cancer-related gene variants, particularly single nucleotide variants (SNVs). Quest, with its expertise in oncology, genomics, and pathology, along with a national scale in tumor biopsy and blood specimen collection, will contribute to the collaboration. The company, known for its comprehensive oncology services, aims to improve diagnostics and treatment monitoring for various health systems and providers in the United States.

“We are delighted to collaborate with the world’s leading diagnostics information services provider to deploy our technology toward lab-developed tests for applications benefiting from insights from whole genome sequencing,” said CEO Gilad Almogy. “Ultima’s technology was designed for applications requiring greater sequencing depth, breadth, or frequency and both MRD testing and whole genome sequencing are premier examples of these. Our unique advantages in SNV detection, combined with greater sequencing depth at lower cost can be transformational for oncology applications and MRD, as well as for cell-free DNA applications and applications with challenging samples. The collaboration with Quest emphasizes our focus on enabling the leading organizations that will help us scale our technology and, most importantly, benefit patients and providers.”

What You Should Know:

• Medtronic, a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval of its Percept™ RC Deep Brain Stimulation (DBS) system.
• The rechargeable neurostimulator is the latest innovation in the Medtronic Percept™ family, which includes the Percept™ PC neurostimulator, BrainSense™ technology, and SenSight™ directional leads. The Percept™ family is the only sensing-enabled DBS system on the market, allowing the physician to personalize treatment for patients with movement disorders such as Parkinson’s disease, essential tremor, and dystonia as well as epilepsy. 

Medtronic’s Perception RC with BrainSense Spearheads Cutting-Edge Management for Pathological Tremor

DBS utilizes a surgically implanted medical device, resembling a cardiac pacemaker. Medtronic’s Percept™ neurostimulators employ slender wires to transmit electrical signals to specific brain targets affected by neurological disorders such as Parkinson’s disease. The Percept™ RC, the smallest and thinnest dual-channel neurostimulator for DBS, incorporates BrainSense™ technology to capture and record brain signals. 

This allows healthcare providers to tailor and personalize therapy based on evolving patient needs. The Percept™ RC battery, featuring Medtronic’s patented technology, offers a service life of at least 15 years with consistent and fast recharge performance, exhibiting less battery fade than other rechargeable devices. Patients can achieve rapid recharging from 10% to 90% full charge in less than an hour. Notably, Medtronic was the first in the U.S. to provide full-body MR Conditional DBS systems, enabling patients to undergo safe scans anywhere on the body under specific conditions. This is crucial as nearly 70 percent of all DBS-eligible patients may require an MRI as part of their essential care.

“Our DBS therapy with exclusive BrainSense™ technology can help control debilitating tremors for people living with Parkinson’s, providing patients with the ability to physically engage in everyday moments – something many of us unintentionally take for granted,” said Amaza Reitmeier, vice president and general manager, Brain Modulation within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. “We are transforming brain modulation through sensing-enabled DBS and will continue to drive therapy innovation with the goal of many more peoples’ lives improved with Medtronic DBS therapy.”

What You Should Know:

• Butterfly Network, Inc. (“Butterfly”), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today announced the FDA clearance of its next-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3.
• The new device is the company’s third iteration of the world’s first semiconductor-based single-probe, whole-body ultrasound system. Butterfly iQ3 features a brand-new ergonomic design and will deliver double the data processing speed for optimized image resolution, sensitivity and penetration, as well as faster 3D capabilities to power novel, automated image capture modes: iQ Slice and iQ Fan.

What You Should Know:

• Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionise healthcare and improve the human condition using molecular science and AI, and Flatiron Health, a leading health-tech company transforming evidence generation through an engaged care network, oncology-specific expertise, and fit-for-purpose scientific methods and tools, today announced a partnership to create a multimodal data offering to support and accelerate biopharmaceutical drug development and patient care.
• As the pioneer in precision medicine and molecular profiling, Caris has created a molecular-rich, real-world database that contains more than 50 petabytes of oncology-specific genomic, transcriptomic, proteomic and imaging data. Caris was the first in the molecular diagnostic industry to provide Whole Exome Sequencing DNA coverage and Whole Transcriptome Sequencing RNA coverage (WES / WTS) for every patient tested. 

Accelerating Advancements for Cancer Drug Discovery

Combining the breadth and depth of Caris’ genomic, transcriptomic and imaging database with Flatiron’s industry-leading longitudinal patient data and high-quality clinical outcomes, backed by deep scientific expertise, equips cancer researchers with robust comprehensive real-world data (RWD) offering at scale to power the next wave of cancer therapeutics.

“We are excited to collaborate with Flatiron Health to create a multimodal data offering in support of biopharma’s efforts to bring novel personalized therapeutic interventions to market to ultimately improve the lives of cancer patients,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. “In forming this data union, we are able to maximize biological and clinical context to better understand each patient journey.” 

What You Should Know:

• Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence and insights, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can so that patients don’t suffer while cures hide on the pharmacy shelf.
• The collaboration allows Every Cure to leverage GENEVA OS™ and data from the Atropos Evidence™ Network to confirm and enhance findings from their AI driven data platform in the real world. By doing this, it offers key real world signals and generation of AI model features to emulate the effect of therapies in real world populations. This rapid, high quality evidence generation dramatically accelerates the potential of yielding new uses for existing drugs and can accelerate clinical development by providing a real-world signal of patient response. 

Unlocking the Full Potential of Modern Medicine

Since its inception in 2023, the collaboration has pioneered a Real-World Data-driven approach named “Biology-in-Data Out” and “Data-in-Biology Out.” This method, employed by Every Cure, involves utilizing their AI platform to identify potential drug repurposing signals, which are then validated in real-world patients through the GENEVA OS and the Atropos Evidence Network. Recently featured in a Cell Publication by Dr. Dylan Dodd at Stanford University, this approach utilizes Atropos Health to confirm the impact of the antibiotic Bactrim on gout symptoms by analyzing shifts in gut bacteria populations.

Coinciding with the launch of Geneva OS™ and ChatRWD™, Atropos Health, a leader in life sciences, has also formed a Life Sciences Advisory Board featuring executives from prominent pharmaceutical companies such as Moderna and Novartis. Every Cure and other partners gain access to Atropos’ evidence generation tools through a federated installation of Geneva OS in their internal cloud data environment. This includes the Green Button Informatics Consult and access to Alexandria™, housing thousands of existing studies for rerunning on local data. Furthermore, Geneva OS incorporates the CRAFT Emulation Toolkit™, allowing users to enhance trial recruitment and analyze trial designs in real-world data, facilitating diverse subgroup analysis for optimizing study designs. CRAFT Emulation Toolkit accelerates evidence generation, maintaining Atropos Health’s commitment to swift insights.

What You Should Know:

– Samsung Health, according to Hon Pak, Vice President and Head of Digital Health Team, MX Business at Samsung Electronics, aims to assist individuals in comprehending and handling their health through a comprehensive platform that connects devices, services, and people.

– The inclusion of the new Medications tracking feature is anticipated to enhance users’ ability to conveniently manage their medications, improve adherence, and ultimately maintain better health overall.

Enhancing the Consumer Management of Medications Via Samsung Health

Entering the name of a specific medication into Samsung Health activates the Medications feature, furnishing users with comprehensive information, including general descriptions and potential side effects. The feature also highlights adverse reactions resulting from drug interactions or co-administration with certain foods and substances like caffeine and alcohol. As an illustration, if a user is taking Simvastatin, Samsung Health will caution about serious side effects associated with combining the drug with grapefruit juice. Users have the option to log the shape and color of their medications, facilitating easy differentiation between pills. Additionally, users can input dosage, consumption time, and other details to prevent confusion.

Samsung Health enables users to configure alerts reminding them when to take medications and when to consider refilling prescriptions. These alerts are personalized, allowing the Medications feature to prioritize reminders based on importance. Samsung Health sends reminders ranging from “gentle” to “strong” depending on the urgency of a prescription. Crucial medications can trigger a “strong” reminder, presenting a full-screen alert on the smartphone accompanied by a long tone. For supplements like vitamins, a discreet pop-up reminder appears. Galaxy Watch users receive reminders on their wrist, ensuring they stay on track with medication schedules, even when without their phones.

In addition to its Medications tracking feature, the Samsung Health app offers advanced health services encompassing sleep management, mindfulness programs, and irregular heart rhythm detection capabilities. By integrating the Medications feature, Samsung Health provides a holistic wellness experience, empowering users to lead healthier lifestyles while effectively managing their medication regimens.

What You Should Know:

• knownwell, a fully integrated virtual and in-person weight-inclusive healthcare company, today announced the launch of knownwell teens, an early intervention clinical offering designed to support the 14 million children and teens living with obesity in the United States.
• Created by knownwell’s renowned metabolic health experts, this new model aims to empower patients on their wellness journey through the company’s clinically-rigorous care model.

Redoubling the Commitment to Preventative Metabolic Healthcare

The existing healthcare system in the United States faces a clear challenge related to weight bias, often causing both children and adults to feel marginalized based on their body weight. In response to this issue, knownwell addresses weight bias by establishing a patient-centric environment where the care team collaborates with patients to achieve their health and wellness objectives. knownwell’s approach involves a comprehensive clinical strategy to identify and treat the root causes of early obesity, incorporating nutritional counseling and behavioral health services. This stands in contrast to the commonly used stigmatizing and diet-focused approach for individuals aged 12 to 18.

Dr. Angela Fitch, Chief Medical Officer at knownwell and President of the Obesity Medicine Association, emphasized the need for a clinical approach to combat the childhood onset of chronic obesity. She explained, “We’ve recognized for an extended period that the chronic disease of obesity often originates in childhood, yet there has been minimal effort from a genuinely clinical standpoint to address this escalating epidemic. That’s why we’ve developed a groundbreaking metabolic health program specifically tailored for adolescents, aiming to treat the underlying metabolic health condition without resorting to shaming or instructing children on dieting.”

Notably, GLP-1s like Semaglutide have already received FDA approval for treating obesity in teens aged 12 and older. A 2022 clinical trial demonstrated a 16.1 percent reduction in body mass index (BMI) in teens with obesity who received Wegovy injection compared to those who received a placebo. By providing access to such medications, adolescents now have an additional treatment option to complement the behavioral and lifestyle changes facilitated by knownwell. Through early intervention and a focus on metabolic health, knownwell strives to contribute to a healthier America, reducing the risk of chronic diseases such as type two diabetes and cardiovascular disease.